For: | Zhu SG, Li HB, Dai TX, Li H, Wang GY. Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report. World J Clin Cases 2022; 10(27): 9743-9749 [PMID: 36186195 DOI: 10.12998/wjcc.v10.i27.9743] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v10/i27/9743.htm |
Number | Citing Articles |
1 |
Fei Chen, Jian Sheng, Xiaoping Li, Zhaofeng Gao, Siqi Zhao, Lingyu Hu, Minjie Chen, Jianguo Fei, Zhengwei Song. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma. Biomedicine & Pharmacotherapy 2024; 175: 116659 doi: 10.1016/j.biopha.2024.116659
|
2 |
Feng Xian, Dacheng Ren, Jun Bie, Guohui Xu. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1119168
|
3 |
Ruyu Han, Peipei Song, Wei Tang, Tianqiang Song, Lu Chen. Advances in neoadjuvant therapy for resectable intrahepatic cholangiocarcinoma: An invited commentary. Oncology and Translational Medicine 2024; doi: 10.1097/ot9.0000000000000068
|